Idelalisib
August 6, 2024
Idelalisib is used in combination with another medication (rituximab) only after the disease has relapsed or is no longer responding to other CLL and SLL treatments.
Idelalisib is used in combination with another medication (rituximab) only after the disease has relapsed or is no longer responding to other CLL and SLL treatments.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial.
This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.
Dr. Jeff Sharman and colleagues presented this research at the American Society for Hematology annual meeting held December 2021 (ASH 2021).
Idelalisib (Zydelig) was once known as CAL-101 and was the most exciting new oral therapy in the CLL world, the shining morning star in the dawn of a new era of treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL).
CLL patients now have multiple excellent choices between limited-duration and continuous targeted therapies that all can offer durable disease control. Choosing between them depends on multiple factors.
October 2025 CLL Bloodline: Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Access important medications in the CLL Society Clinician Medicine Cabinet. Download key resources and order a Welcome Kit.
Pirtobrutinib provides longer progression-free survival and is safer than idelalisib-rituximab and bendamustine-rituximab for treating relapsed CLL.